Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience.

CONCLUSIONS: Bortezomib may be an effective option for refractory LN, but close monitoring must be performed for possible adverse events such as peripheral neuropathy and hypogammaglobulinemia.
PMID: 31865857 [PubMed - as supplied by publisher]

Source: Lupus - December 21, 2019 Category: Rheumatology Authors: Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, Ramos N, Carnicer C, Valtierra N, Ostos E Tags: Lupus Source Type: research